SK Bioscience Signs Vaccine Technology Transfer and Production Cooperation Agreement with Colombia
Participation in $260 Million Vaccine Localization Project
Collaboration with State-Owned Pharmaceutical Company VECOL
On May 26, SK bioscience announced that it had signed an agreement with VECOL, Colombia's state-owned pharmaceutical company, for vaccine technology transfer and local production cooperation.
This agreement is part of Colombia's national vaccine localization project, which is led by the Ministry of Health and Social Protection, and jointly promoted by the National Institute of Health (INS) and VECOL. The project is a large-scale national initiative in which approximately 260 million dollars (about 350 billion won) will be invested over the next 10 years, with the Colombian government aiming to establish a foundation for vaccine self-sufficiency and strengthen the country's public health capabilities.
VECOL has been designated by the Colombian government as the lead implementing agency for the project and will oversee overall execution. SK bioscience will participate as the partner for vaccine technology transfer and local production cooperation.
Previously, over a period of about four years, the Colombian government conducted a comprehensive evaluation of several global companies with World Health Organization (WHO) vaccine production experience, assessing technology, regulatory standards, collaboration capabilities, and alignment with long-term strategies. As a result, SK bioscience was highly rated for its global business experience, rigorous quality and regulatory management systems, experience with WHO prequalification (PQ) vaccine production, and willingness to cooperate on long-term national capacity-building projects, and was ultimately selected as the final partner.
Going forward, SK bioscience will be responsible for building production facilities in Colombia, introducing products, and transferring the technology and know-how required for regulatory approval and production operations. VECOL will oversee the establishment and operation of production facilities, securing government permits, integrating with the National Immunization Program (NIP), and cooperating with government agencies.
The initial target for technology transfer is the chickenpox vaccine 'Skyvaricella.' SK bioscience plans to establish a local production and technology transfer system based on its proprietary vaccine, Skyvaricella, and is considering expanding cooperation to additional vaccine product lines in the future. In addition, SK bioscience will retain priority negotiation rights if the Colombian government utilizes the facilities for other SK bioscience vaccines or for a variety of products that the government may choose to introduce in the future.
SK bioscience has also received a request from the Pan American Health Organization (PAHO) to supply 950,000 doses of Skyvaricella for Colombia within this year, and has secured a final purchase order for 600,000 doses. This follows the decision by the Colombian Ministry of Health and Social Protection to switch the entire annual chickenpox vaccine requirement for the National Immunization Program (NIP)—a total of 950,000 doses—to Skyvaricella this year.
Colombia is a key vaccine market in Central and South America, with a national immunization system. In the wake of the pandemic, the importance of stable vaccine supply chains and health security has become more prominent, leading to rapidly increasing demand for establishing local production bases and technology cooperation.
The vaccine localization project promoted by SK bioscience and the Colombian government is expected to contribute not only to Colombia but also to the establishment of a stable vaccine supply base throughout the wider Latin American region. SK bioscience plans to use this collaboration as a foothold for securing a production base in Latin America and expanding technology transfer projects in LATAM, with a strategy to broaden cooperation with neighboring countries and complete a hub-type vaccine supply and production system.
The Colombian Ministry of Health and Social Protection described the agreement between VECOL and SK bioscience as a strategic milestone for strengthening Colombia’s health sovereignty. The ministry also emphasized that this case demonstrates Colombia’s determination to rebuild its scientific, technological, and industrial capabilities at a national level, going beyond simple vaccine production cooperation. Furthermore, the ministry stated that, based on knowledge transfer, the training of skilled professionals, and the establishment of world-class infrastructure, the project is expected to strengthen domestic production capabilities in research, innovation, and strategic health technologies, reduce external dependency, and secure long-term sustainability.
Gina Tambini Gomez, Colombia Country Representative for PAHO/WHO, said, "We highly value Colombia's step toward strengthening health sovereignty through the agreement between VECOL and SK bioscience," adding, "This collaboration is a meaningful advance toward achieving the shared goal of strengthening health technology production capabilities in Latin America, and PAHO will continue to support these efforts by strengthening regional innovation and production platforms, advancing regulatory systems, and expanding joint procurement mechanisms."
Lucia Ayala, CEO of VECOL, stated, "This agreement will be a turning point in strengthening the country's scientific and technological capabilities," adding, "Beyond simple biotechnology transfer, we will accumulate knowledge and capabilities, and lay the foundation for the long-term recovery of strategic capabilities in public health and health sovereignty."
Jae-Yong Ahn, CEO of SK bioscience, said, "We are honored to participate in the national project to strengthen vaccine production capacity being promoted by the Colombian government and VECOL," and added, "Based on our accumulated capabilities in vaccine development and production and our global collaboration experience, we will strive to contribute to future infectious disease response and the establishment of a sustainable vaccine supply base."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Meanwhile, since its first successful bid for PAHO chickenpox vaccine procurement in 2022, SK bioscience has been steadily building trust by supplying products to the Latin American market. Last year, the supply period for PAHO chickenpox vaccines was extended to 2027, once again proving the competitive edge of SK bioscience products. Skyvaricella is a chickenpox vaccine that, in 2019, became the second in the world to obtain WHO PQ (prequalification) certification.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.